ArticleJournal of virology2004
Lysines close to the Rous sarcoma virus late domain critical for budding.
Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 31 citations in OpenAlex.
- Post-Translational Modifications of Retroviral HIV-1 Gag Precursors: An Overview of Their Biological Role.International journal of molecular sciences · 2021Review
- L-Lysine as the Molecule Influencing Selective Brain Activity in Pain-Induced Behavior of Rats.International journal of molecular sciences · 2019Article
- Virus budding and the ESCRT pathway.Cell host & microbe · 2013Review
- Role of ubiquitin in parainfluenza virus 5 particle formation.Journal of virology · 2012Article
- CRM1-dependent trafficking of retroviral Gag proteins revisited.Journal of virology · 2012Article
- How ubiquitin functions with ESCRTs.Traffic (Copenhagen, Denmark) · 2011Review
- Multiple interactions between the ESCRT machinery and arrestin-related proteins: implications for PPXY-dependent budding.Journal of virology · 2011Article
- Viral takeover of the host ubiquitin system.Frontiers in microbiology · 2011Article
- Functional interchangeability of late domains, late domain cofactors and ubiquitin in viral budding.PLoS pathogens · 2010Article
- Conserved motifs within Ebola and Marburg virus VP40 proteins are important for stability, localization, and subsequent budding of virus-like particles.Journal of virology · 2010Article
- Late domain-independent rescue of a release-deficient Moloney murine leukemia virus by the ubiquitin ligase itch.Journal of virology · 2010Article
- Hepatitis B virus replication and release are independent of core lysine ubiquitination.Journal of virology · 2009Article
- The Mechanism of Budding of Retroviruses From Cell Membranes.Advances in virology · 2009Article
- Functional replacement of a retroviral late domain by ubiquitin fusion.Traffic (Copenhagen, Denmark) · 2008Article
- Avian sarcoma virus and human immunodeficiency virus, type 1 use different subsets of ESCRT proteins to facilitate the budding process.The Journal of biological chemistry · 2008Article
- Cooperative role of the MHR and the CA dimerization helix in the maturation of the functional retrovirus capsid.Virology · 2008Article
- Efficient and specific rescue of human immunodeficiency virus type 1 budding defects by a Nedd4-like ubiquitin ligase.Journal of virology · 2008Article
- Ubiquitin-dependent virus particle budding without viral protein ubiquitination.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- The role of WWP1-Gag interaction and Gag ubiquitination in assembly and release of human T-cell leukemia virus type 1.Journal of virology · 2007Article
- Genetic Studies of the beta-hairpin loop of Rous sarcoma virus capsid protein.Journal of virology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
The release of retroviruses from the plasma membrane requires host factors that are believed to be recruited to the site of budding by the late (L) domain of the virus-encoded Gag protein. The L domain of Rous sarcoma virus (RSV) has been shown to interact with a ubiquitin (Ub) ligase, and budding of this virus is dependent on Ub. RSV is similar to other retroviruses in that it contains approximately 100 molecules of Ub, but it is unique in that none of these molecules has been found to be conjugated to Gag. If transient ubiquitination of RSV Gag is required for budding, then replacement of the target lysine(s) with arginine should prevent the addition of Ub and reduce budding. Based on known sites of ubiquitination in other viruses, the important lysines would likely reside near the L domain. In RSV, there are five lysines located just upstream of the L domain in a region of the matrix (MA) protein that is dispensable for membrane binding, and replacement of these with arginine (mutant 1-5KR) reduced budding 80 to 90%. The block to budding was found to be on the plasma membrane; however, the few virions that were released had normal size, morphology, and infectivity. Budding was restored when any one of the residues was changed back to lysine or when lysines were inserted in novel positions, either within this region of MA or within the downstream p10 sequence. Moreover, the 1-5KR mutant could be rescued into particles by coexpression of budding-competent Gag molecules. These data argue that the phenotype of mutant 1-5KR is not due to a conformational defect. Consistent with the idea that efficient budding requires a specific role for lysines, human T-cell leukemia virus type 1, which does not bud well compared to RSV and lacks lysines close to its L domain, was found to be released at a higher level upon introduction of lysines near its L domain. This report strongly supports the hypothesis that ubiquitination of the RSV Gag protein (and perhaps those of other retroviruses) is needed for efficient budding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.